回盛生物(300871) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥206,809,092.09, a decrease of 10.24% compared to ¥230,412,076.04 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥16,405,616.80, representing a decline of 210.43% from a profit of ¥14,855,718.00 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 206,809,092.09, a decrease of 10.3% compared to CNY 230,412,076.04 in the same period last year[25] - Net profit for Q1 2024 was a loss of CNY 16,405,616.80, compared to a profit of CNY 14,855,718.00 in Q1 2023, indicating a significant decline in profitability[27] - The weighted average return on equity was -1.08%, down from 0.96% in the same period last year, indicating a decline in profitability[5] Cash Flow - The net cash flow from operating activities was -¥46,279,493.65, a decrease of 169.38% compared to -¥17,180,234.31 in the same period last year[14] - Cash flow from operating activities showed a net outflow of CNY 46,279,493.65, worsening from a net outflow of CNY 17,180,234.31 in the same quarter last year[30] - The net cash flow from investment activities was -76,332,192.37 CNY, compared to -88,514,280.15 CNY in the previous year, indicating a slight improvement[31] - Cash inflow from financing activities totaled 202,776,473.00 CNY, up from 136,340,072.90 CNY year-over-year[31] - The net cash flow from financing activities increased to 95,204,302.87 CNY, compared to 64,595,118.87 CNY in the same period last year[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,993,838,428.76, reflecting a slight increase of 0.62% from ¥2,975,460,462.12 at the end of the previous year[5] - The total liabilities of the company increased to CNY 1,277,604,103.83, compared to CNY 1,265,980,935.65 in the previous quarter[20] - The total liabilities as of Q1 2024 amounted to CNY 1,484,056,241.74, compared to CNY 1,466,179,400.00 at the end of the previous year[23] - The total equity attributable to shareholders was CNY 1,509,782,187.02, slightly up from CNY 1,509,281,062.12 year-on-year[23] Expenses - Research and development expenses increased by 56.52% to ¥14,535,112.78 from ¥9,286,444.32 year-on-year[13] - The company reported a significant increase in financial expenses by 93.30% to ¥9,782,201.46, primarily due to the capitalization of convertible bond interest[13] - Total operating costs for Q1 2024 were CNY 219,314,493.26, slightly down from CNY 220,505,096.35 year-on-year[26] - The company recorded a significant increase in financial expenses, with interest expenses rising to CNY 10,410,980.81 from CNY 5,391,289.96 year-on-year[26] Shareholder Information - The company reported a total of 82,800,000 shares held by its largest shareholder, Wuhan Tongsheng Investment Co., Ltd., representing 49.91% of the total shares[17] Other Information - The company has not disclosed any new product developments or market expansion strategies in this quarter's report[18] - The company did not undergo an audit for the first quarter report[32] - The company began implementing new accounting standards starting in 2024[32]